Strong trial results, but not approved and not legal to sell
Four large Phase 3 trials reported major weight loss. Eli Lilly plans to apply for FDA approval in early 2027. Until approval, any retatrutide sold to consumers is an unapproved drug of unknown quality.
Retatrutide is the most talked-about weight-loss drug that you can't get yet. Its clinical trial results are genuinely striking, which is exactly why a gray market has grown up around it. Here's what's known as of October 27, 2026.
What retatrutide is
Retatrutide is an investigational once-weekly injection developed by Eli Lilly. It's sometimes called a "triple agonist" because it acts on three hormone receptors involved in appetite and metabolism: GLP-1, GIP, and glucagon. For comparison, semaglutide (Ozempic, Wegovy) acts on one, and tirzepatide (Mounjaro, Zepbound) acts on two.
What the Phase 3 trials found
Lilly's TRIUMPH program includes four core Phase 3 trials, all of which reported positive results by July 2026:
| Trial | Who was studied | Average weight loss, highest dose | Reported |
|---|---|---|---|
| TRIUMPH-4 | Obesity with knee osteoarthritis | 28.7% at 68 weeks | December 2025 |
| TRIUMPH-1 | Obesity without diabetes (2,339 adults) | 28.3% at 80 weeks* | May 2026 |
| TRIUMPH-2 | Obesity or overweight with type 2 diabetes | 20.8% at 80 weeks | July 2026 |
| TRIUMPH-3 | Severe obesity with heart disease | 22.6% at 80 weeks | July 2026 |
*TRIUMPH-1, published in the New England Journal of Medicine in September 2026, reported 28.3% among people who took the drug as intended, and 25.0% when counting everyone who started the trial. People on placebo lost about 2% to 4%.
These are among the largest average weight losses ever reported for a medication.
Side effects and dropouts
Like other drugs in this class, retatrutide's most common side effects are digestive. More people stopped taking retatrutide because of side effects than stopped taking placebo. In TRIUMPH-3, 13.5% stopped on the highest dose versus 4.8% on placebo. Full safety data will come with the FDA review.
When could it be approved?
Lilly says it plans to submit an application for FDA approval in the first quarter of 2027. A typical FDA review takes about 10 to 12 months after submission, so approval, if it comes, would most likely be in late 2027 or 2028. Until then, retatrutide isn't available by prescription for any use outside clinical trials.
The gray market
Because the trial results are so strong, retatrutide is widely sold online as a "research peptide." Those products are unapproved drugs, not retatrutide from Lilly, and nothing guarantees what's actually in the vial.
Regulators and Lilly are pushing back:
- The FDA has cited retatrutide in more than 20 warning letters to online sellers since December 2024, including a batch of five dated August 24, 2026.
- In August 2026, Lilly sued six companies selling retatrutide.
For more, see every FDA warning letter to peptide sellers and what "research use only" really means.
The bottom line
Retatrutide may well become an important obesity treatment. The safest way to get it is the same as for any drug: through a clinical trial now, or by prescription after FDA approval. If you're interested in medication for weight loss today, semaglutide and tirzepatide are FDA-approved and available by prescription.
What this article is based on
Checked October 27, 2026. Primary FDA documents are listed first where available.
- Eli Lilly: Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026)
- PharmExec: Retatrutide delivers up to 22.6% weight loss in two new Phase III trials
- Wikipedia: Retatrutide (TRIUMPH-1 published results summary)
- VialAudit: FDA peptide enforcement 2024–2026, letters and lawsuits
- Veloxpeps: FDA warning letters to five online peptide sellers (September 2026)
About this content: The Peptide Verdict is an independent educational publication. Articles are researched and written with AI assistance, edited by our editorial team, and checked against the primary sources listed on each page. They are not reviewed by a medical professional and are not medical, legal, or pharmacy advice. Peptide regulations change quickly; always check the dates shown and confirm current rules. Talk to a licensed clinician before using any peptide or medication.